Tempus AI Inc (NASDAQ:TEM) stock is trading higher on Thursday morning following a key product expansion announcement.
The company revealed a significant expansion of new indications for its AI-enabled Next platform.
The update comes just ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The platform establishes a new category of real-time clinical intelligence to advance precision medicine, moving away from legacy retrospective analyses.
Expanding Cancer Scenario Insights
The expanded platform will now surface patient insights across six new clinical scenarios. These cover breast, colorectal, ovarian, prostate and urothelial cancers.
Additionally, Next introduced advanced intelligence capabilities. These features allow precision medicine teams to map patient experiences and develop targeted care gap programs.
To showcase the real-world impact, Tempus will present a study at ASCO 2026 demonstrating improvements in biomarker testing rates for early-stage non-small cell lung cancer (eNSCLC).
Eliminating Data Fragmentation
The platform analyzes unstructured EHR data to identify patients missing guideline-directed testing.
“The true challenge in precision oncology is the data fragmentation that hides critical care gaps across the patient journey,” stated Ryan Fukushima, CEO of Data and Apps at Tempus, in the announcement. “By expanding Next, we are providing our health systems partners with a 360-degree view to not only identify these gaps but to quantify the truly addressable opportunities for intervention.”
Critical Levels To Watch for TEM Stock
TEM is back above its shorter-term trend gauges, trading 4.6% above the 20-day SMA and 4.1% above the 50-day SMA, which helps explain why dip-buyers are showing up on Thursday.
The bigger picture is still heavy, though, with shares 5.5% below the 100-day SMA and 22.9% below the 200-day SMA.
The moving-average structure also argues this is still a repair phase: the 20-day SMA remains below the 50-day SMA, and the death cross (50-day below the 200-day) that triggered in January is still in place.
RSI is the cleaner momentum read right now, sitting at 45.66.
From a level-to-level standpoint, the stock is still well off its 52-week high of $104.32 and closer to the lower end of the range after the March swing low and 52-week low zone.
- Key Resistance: $56.50
- Key Support: $42.50
TEM Price Action: Tempus AI shares were up 8.36% at $51.11 at the time of publication on Thursday, according to Benzinga Pro data.
Photo: bella1105 / Shutterstock
Recent Comments